Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P56159
UPID:
GFRA1_HUMAN
Alternative names:
RET ligand 1; TGF-beta-related neurotrophic factor receptor 1
Alternative UPACC:
P56159; A8KA21; O15507; O43912
Background:
GDNF family receptor alpha-1, also known as RET ligand 1 or TGF-beta-related neurotrophic factor receptor 1, plays a pivotal role in kidney and urinary tract development. It functions as a receptor for GDNF, facilitating the GDNF-induced autophosphorylation and activation of the RET receptor. This process is crucial for the proper development and function of the renal system.
Therapeutic significance:
The protein is directly linked to Renal hypodysplasia/aplasia 4, a severe congenital anomaly characterized by bilateral renal agenesis. Understanding the role of GDNF family receptor alpha-1 in this condition could pave the way for innovative therapeutic strategies aimed at mitigating or potentially curing this fatal disease.